SK132596A3 - The use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (hp) associated syndromes and infectious diseases - Google Patents

The use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (hp) associated syndromes and infectious diseases Download PDF

Info

Publication number
SK132596A3
SK132596A3 SK1325-96A SK132596A SK132596A3 SK 132596 A3 SK132596 A3 SK 132596A3 SK 132596 A SK132596 A SK 132596A SK 132596 A3 SK132596 A3 SK 132596A3
Authority
SK
Slovakia
Prior art keywords
therapy
dimeticone
prevention
helicobacter pylori
infectious diseases
Prior art date
Application number
SK1325-96A
Other languages
English (en)
Slovak (sk)
Inventor
Alfred Schmidt
Hans-Jurgen Upmeyer
Original Assignee
Alfred Schmidt
Upmeyer Hans Juergen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfred Schmidt, Upmeyer Hans Juergen filed Critical Alfred Schmidt
Publication of SK132596A3 publication Critical patent/SK132596A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
SK1325-96A 1994-03-18 1995-03-15 The use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (hp) associated syndromes and infectious diseases SK132596A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4409410 1994-03-18
PCT/EP1995/000972 WO1995025525A1 (fr) 1994-03-18 1995-03-15 Utilisation de dimeticone dans la therapie antibacterienne locale et/ou la prevention et la therapie des syndromes et maladies infectieuses associes a helicobacter pylori (hp)

Publications (1)

Publication Number Publication Date
SK132596A3 true SK132596A3 (en) 1997-08-06

Family

ID=6513239

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1325-96A SK132596A3 (en) 1994-03-18 1995-03-15 The use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (hp) associated syndromes and infectious diseases

Country Status (13)

Country Link
US (1) US5834004A (fr)
EP (1) EP0759761A1 (fr)
JP (1) JPH09510465A (fr)
CN (1) CN1146154A (fr)
AU (1) AU706351B2 (fr)
CA (1) CA2185883C (fr)
CZ (1) CZ300696A3 (fr)
FI (1) FI963683A7 (fr)
HU (1) HUT75710A (fr)
NO (1) NO963892L (fr)
NZ (1) NZ282804A (fr)
SK (1) SK132596A3 (fr)
WO (1) WO1995025525A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1097456C (zh) * 1997-12-22 2003-01-01 永信药品工业股份有限公司 胃肠消泡锭剂的制造方法及其应用
US6279577B1 (en) 1998-12-21 2001-08-28 Carl A. Savaiano Supporter
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis
CN1288730A (zh) * 1999-09-07 2001-03-28 麦克内尔-Ppc股份有限公司 轻泻组合物
KR100442174B1 (ko) * 2001-09-25 2004-07-30 (주)다산메디켐 이산화규소, 폴리소르베이트류 및디메칠폴리실록산(디메치콘, 시메치콘)을 함유하는소화기장애에 사용되는 고형의 신규의약조성물
US7252846B2 (en) * 2004-05-28 2007-08-07 Raied Dinno Topical composition and method for the treatment and prophylaxis of dermal irritations
DE102008037168A1 (de) 2008-08-06 2010-06-24 Nowak, Götz, Prof. Dr. Verwendung von Sauerstoff zur Behandlung von Erkrankungen der Schleimhaut des Magen-Darm-Kanals

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3848M (fr) * 1964-05-04 1966-01-17 Robert Schapiro Associations thérapeutiques pour traitement de nombreux troubles digestifs organiques ou fonctionnels.
GB1357737A (en) * 1970-10-09 1974-06-26 Arpic Sa Sustained release pharmaceutical compositions
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
DE3642853A1 (de) * 1986-12-16 1988-06-23 Ulrich Von Dr Ing Pidoll Arzneimittel
US4960764A (en) * 1987-03-06 1990-10-02 Richardson-Vicks Inc. Oil-in-water-in-silicone emulsion compositions
US4837029A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Low foaming, aqueously homogenizable rifampin composition
DE3807712A1 (de) * 1987-07-25 1989-02-02 Nordend Apotheke Angela Hein Arzneimittel-trockenpraeparat zur bereitung einer laxativ wirkenden trinkloesung sowie ein verfahren zur herstellung dieses praeparates
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
AU637570B2 (en) * 1989-01-19 1993-06-03 Alfred Schmidt Use of dimethylpolysiloxane for treating disorders of the gastrointestinal tract
US5422093A (en) * 1989-07-28 1995-06-06 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
IL95642A0 (en) * 1989-09-15 1991-06-30 Pehrom Pharmaceutical Corp Topical preparations for treatment of ulcers and other lesions
NZ235876A (en) * 1989-11-01 1992-06-25 Mcneil Ppc Inc Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
WO1994003209A1 (fr) * 1992-07-29 1994-02-17 Merck & Co., Inc. Combinaisons dexibuprofene/antacide/simethicone

Also Published As

Publication number Publication date
HU9602841D0 (en) 1996-12-30
FI963683L (fi) 1996-11-13
CZ300696A3 (en) 1997-09-17
WO1995025525A1 (fr) 1995-09-28
NO963892D0 (no) 1996-09-17
AU706351B2 (en) 1999-06-17
CA2185883A1 (fr) 1995-09-28
FI963683A0 (fi) 1996-09-17
CN1146154A (zh) 1997-03-26
AU2071495A (en) 1995-10-09
HUT75710A (en) 1997-05-28
JPH09510465A (ja) 1997-10-21
US5834004A (en) 1998-11-10
NZ282804A (en) 2000-12-22
CA2185883C (fr) 2005-08-23
FI963683A7 (fi) 1996-11-13
NO963892L (no) 1996-11-04
EP0759761A1 (fr) 1997-03-05

Similar Documents

Publication Publication Date Title
Graham et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial
Hosking et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial
Oderda et al. Campylobacter pylori gastritis: long term results of treatment with amoxycillin.
Tytgat et al. Campylobacter pylori and its role in peptic ulcer disease
Marshall One hundred years of discovery and rediscovery of Helicobacter pylori and its association with peptic ulcer disease
Axon Helicobacter pylori infection
Ramakrishna et al. Aegle marmelos fruit extract attenuates Helicobacter pylori Lipopolysaccharide induced oxidative stress in Sprague Dawley rats
EP1112074B1 (fr) Taurolidine et/ou taurultam destines a la lutte contre les ulceres ou les gastrites d'origine infectieuse
Figueroa et al. Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
CZ300696A3 (en) USE OF DEMETICON FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR LOCAL AND ANTIBACTERIAL THERAPY AND/OR PREVENTION AND THERAPY OF SYNDROMES AND INFECTIOUS DISEASES CONNECTED WITH HELIOBACTER PYLORI (Hp)
Louw et al. Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates
Catalano et al. Helicobacter pylori-Positive Functional Dyspepsia in Elderly Patients Comparison of Two Treatments
Labenz et al. Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease
AU699199B2 (en) The use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (HP) associated syndromes and infectious diseases
US5229380A (en) Method for treating helicobacter pylori gastritis
Ohkusa et al. Prospective evaluation of a new anti‐ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection
Dalla Libera et al. High effectiveness and safety of one‐week antibiotic regimen in Helicobacter pylori eradication
US6028062A (en) Use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (Hp) associated syndromes and infectious diseases
Archimandritis et al. Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine: a 12-month follow-up
Bui et al. Helicobacter pylori affects the quality of experimental gastric ulcer healing in a new animal model
Slomiany et al. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents
SAITA et al. Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy
Huesca et al. Therapeutics used to alleviate peptic ulcers inhibit H. pylori receptor binding in vitro
Levi et al. Campylobacter pylori, duodenal ulcer disease, and gastrin
Lee et al. Evaluation of therapeutic regimens for the treatment of Helicobacter pylori infection